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Abstract—Different aspects of a clinical sample can be revealed
by multiple types of omics data. Integrated analysis of multi-
omics data provides a comprehensive view of patients, which
has the potential to facilitate more accurate clinical decision
making. However, omics data are normally high dimensional with
large number of molecular features and relatively small number
of available samples with clinical labels. The “dimensionality
curse” makes it challenging to train a machine learning model
using high dimensional omics data like DNA methylation and
gene expression profiles. Here we propose an end-to-end deep
learning model called OmiVAE to extract low dimensional
features and classify samples from multi-omics data. OmiVAE
combines the basic structure of variational autoencoders with a
classification network to achieve task-oriented feature extraction
and multi-class classification. The training procedure of OmiVAE
is comprised of an unsupervised phase without the classifier and
a supervised phase with the classifier. During the unsupervised
phase, a hierarchical cluster structure of samples can be automat-
ically formed without the need for labels. And in the supervised
phase, OmiVAE achieved an average classification accuracy of
97.49% after 10-fold cross-validation among 33 tumour types
and normal samples, which shows better performance than other
existing methods. The OmiVAE model learned from multi-omics
data outperformed that using only one type of omics data, which
indicates that the complementary information from different
omics datatypes provides useful insights for biomedical tasks like
cancer classification.
Index Terms—deep learning, variational autoencoders, multi-
omics analysis, DNA methylation, gene expression, pan-cancer
classification
I. INTRODUCTION
The term “omics” refers to a discipline of life sciences
analysing the interactions and functions of various biolog-
ical entities in fields ending in the suffix -omics, encom-
passing genomics, epigenomics, transcriptomics, proteomics,
metabolomics, etc. Thanks to the significant advances in high-
throughput experimental technologies, a large amount of omics
data in different datatypes is generated on an unprecedented
scale [1]. Various types of omics data reveal different aspects
of the same clinical samples. Integrated analysis of multi-
omics data provides a comprehensive view of patients, which
has the potential to facilitate more accurate clinical decision
making.
This project has received funding from the European Unions Horizon 2020
research and innovation programme under the Marie Skodowska-Curie grant
agreement 764281.
Omics data, especially DNA methylation and gene expres-
sion profiles, are normally high dimensional with tens of thou-
sands of or even hundreds of thousands of molecular features.
However, the number of available samples with clinical labels
like diagnostic and prognostic information is relatively small.
To overcome the challenge of “dimensionality curse” and
alleviate overfitting in task like cancer classification, routine
methods manually select a small subset of the molecular
features based on domain knowledge [2] or use traditional
dimensionality reduction algorithms like principal component
analysis (PCA) before the downstream analysis, which may
overlook some genome-wide hidden patterns. During the past
few years, deep learning [3] methods have shown great success
in analysing high-dimensional data like images. Among them,
variational autoencoders (VAE) [4] have been widely applied
to embed image and text data into lower dimensional latent
spaces, whereas the application of VAE for analysing omics
data is still in its early stage.
In this work, we propose a model called OmiVAE for both
low dimensional latent space extraction and multi-class clas-
sification on multi-omics datasets. OmiVAE combines a basic
structure of a VAE with a classification network to achieve
task-oriented feature extraction and end-to-end classification.
We integrated genome-wide DNA methylation and gene ex-
pression profiles together with 450,804 molecular features
from corresponding samples through this model. The training
procedure of OmiVAE is comprised of an unsupervised phase
without the classifier and a supervised phase with the classifier.
Pan-cancer multi-omics datasets from The Cancer Genome
Atlas (TCGA) [5] with 9,081 samples of 33 tumour types
and normal ones were used to evaluate this model. During the
unsupervised phase, a hierarchical cluster structure of samples
can be automatically formed without the need for labels.
The higher-level clusters refer to different organs or sys-
tems. For a specific tissue-of-origin, various tumour subtypes
and normal samples are grouped into corresponding lower-
level clusters. In the supervised phase, OmiVAE achieved
an average classification accuracy of 97.49% using multi-
omics data and 96.42% using only gene expression data after
10-fold cross-validation among 33 tumour types and normal
samples, which shows better performance than other existing
methods. The OmiVAE model learned from multi-omics data
outperformed that using only one type of omics data, which
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indicates that the complementary information from different
omics datatypes provides useful insights for biomedical tasks
like cancer classification.
II. RELATED WORK
Inspired by the breakthrough in computer vision and natural
language processing, many traditional machine learning and
deep learning methods have been applied to multi-omics data
analysis and cancer classification. For example, Chaudhary
et al. [6] applied a traditional autoencoder (AE) framework
to embed selected multi-omics molecular features (35,877 in
total) into a 100-dimensional space and used learned features
to predict survival-risk subgroups of liver cancer patients by k-
means clustering and support vector machine (SVM). Chung
et al. [7] proposed a VAE model based on long short-term
memory (LSTM) for cardiac remodeling using metabolomics
and proteomics time-series data. The models built by these
studies were not end-to-end and the features learned by
AE/VAE were used for downstream tasks outside the network.
Ma and Zhang [8] proposed an end-to-end multi-omics model
using factorization autoencoder to predict disease progression-
free interval events with an average precision of 0.664 for
bladder tumour dataset and 0.746 for glioma dataset.
For cancer classification, Fakoor et al. [9] proposed a model
that combined PCA and sparse autoencoder to learn a repre-
sentation of the original gene expression data and used the
learned features for cancer classification. Stacked denoising
autoencoder (SDAE), another variation of autoencoder, was
also applied to extract features from gene expression profiles
[10]. Way and Greene [11] used a VAE model to extract
a latent space from gene expression data and analysed the
relationship between latent variables and certain phenotypes.
Other methods [12], [13] also applied VAE to reduce the
dimension of methylation data and used the latent variables to
classify subtypes of lung and breast tumours. Rhee et al. [14]
proposed a hybrid model integrating graph convolution neural
network (CNN) and relation network to classify breast cancer
subtypes using gene expression profiles and protein-protein
interaction (PPI) networks. In a more comprehensive study,
Capper et al. [15] developed a central nervous system (CNS)
tumours classification system based on DNA methylation data
using a random forest algorithm and evaluated this method in
actual clinical implementation with promising results.
Most of the above work only focused on cancer identifi-
cation or classification among certain types of cancers. As
for pan-cancer classification, Li et al. [16] trained a model
combined a genetic algorithm and k-nearest neighbors (KNN)
on the TCGA gene expression datasets and achieved an overall
prediction accuracy of 95.6%. Lyu and Haque [17] reshaped
gene expression profiles into 2D images and applied a CNN
to classify 33 tumour types from the TCGA datasets. The
average accuracy of this model was 95.59%. Mostavi et al.
[18] implemented three CNN models on the same datasets
and achieved 95.7% accuracy for 33 tumour types and 95.0%
accuracy for tumour types and normal samples. All of these
studies only used gene expression data for pan-cancer clas-
sification without including complementary information from
other types of omics data.
III. MATERIALS AND METHODS
A. Datasets
Two types of high dimensional omics data, RNA-Seq gene
expression profiles and DNA methylation profiles were used
in OmiVAE. We chose TCGA pan-cancer datasets with 33
various tumour types for both gene expression and DNA
methylation data. The gene expression dataset consists of
11,538 samples, among which 741 samples are normal tissues.
Each gene expression profile is comprised of 60,483 identifiers
referring to corresponding exons. Fragments Per Kilobase of
transcript per Million mapped reads (FPKM) values in this
dataset were log2-transformed. The DNA methylation dataset
contains 9,736 samples, in which 746 samples are normal tis-
sues. DNA methylation profiles in this dataset were produced
by Infinium HumanMethylation450 BeadChip (450K) arrays
with 485,578 probes. The Beta value of each probe indicates
the methylation ratio of the corresponding CpG site. Both
datasets were downloaded from UCSC Xena data portal1 on
April 16th, 2019.
B. Data Preprocessing
Data preprocessing procedures were applied to the datasets
to remove noises and biassed signals. We filtered molecular
features (i.e., exons or CpG sites) according to the following
criteria. For gene expression data, exons located at the Y
chromosome (n = 594), exons with zero expression level in
all samples (n = 1,904) and exons that have missing values
(N/A) in more than 10% of samples (n = 248) were removed.
In total, 2,440 molecular features were removed and 58,043
were kept in the gene expression data.
As for DNA methylation data, probes that can not be
mapped to the human reference genome (hg38) annotation (n =
89,512), control probes that are not located at any chromosome
(n = 2,545), probes targeting the Y chromosome (n = 346)
and probes with missing values in more than 10% samples
(n = 414) were filtered out, which results in a final DNA
methylation feature set of 392,761 CpG sites. These probes
were then grouped into 23 subsets according to their targeting
chromosomes. Different chromosomes have different numbers
of probes and the average is 17,077.
After the filtering step, the remaining missing values in
both datasets were replaced by the mean of corresponding
molecular features. For RNA-Seq gene expression data, the
log2-transformed FPKM measures were normalised to the
range of 0 to 1 due to the input requirement of our model. This
normalisation step is not necessary for Beat values in the DNA
methylation dataset, because they are defined in percentage.
Samples in TCGA that have both gene expression and DNA
methylation profiles were used for multi-omics analysis. We
collected 9081 samples in total, in which 407 were normal
tissue samples.
1https://xenabrowser.net/datapages/
C. VAE/Classification Network
Variational autoencoder (VAE) [4] is a powerful deep gener-
ative model capable of learning meaningful data manifold from
high dimensional data. Given a multi-omics dataset D that
is comprised of N clinical samples
{
x(i)
}N
i=1
with d multi-
omics molecular features, we assume each sample x(i) ∈ Rd
is generated by a latent vector z(i) ∈ Rp, where p  d.
This generation process comprises two major steps: each latent
variable z(i) is generated from prior distribution pθ(z), and
each sample x(i) is generated from conditional distribution
pθ(x|z), where θ is the set of learnable parameters of the
generative network (or decoder). Thereby, the objective of a
generative model with latent variables is the distribution of x,
which is:
pθ(x) =
∫
z
pθ(x|z)pθ(z)dz (1)
The integral in (1) is computationally infeasible, due to the
intractability of the true posterior pθ(z|x). In order to address
this issue, variational distribution qφ(z|x) is introduced to
approximate pθ(z|x), where φ is the set of learnable pa-
rameters of the inference network (or encoder). In the VAE
framework, the encoder and the decoder are jointly optimised
by maximizing the variational lower bound:
Ez∼qφ(z|x) log pθ(x|z)−DKL (qφ(z|x)‖pθ(z)) (2)
where DKL is the KullbackLeibler (KL) divergence between
two probability distributions [19].
In OmiVAE, we combines the basic structure of VAE with
a classification network to achieve task-oriented feature ex-
traction and end-to-end cancer classification. The architecture
of OmiVAE is illustrated in Fig. 1. The network structure is
comprised of three main components: an encoder, a decoder,
and a classifier.
In the encoder network, gene expression and DNA methy-
lation profiles are first encoded into two 1,024 dimensional
vectors separately through two hidden layers. After data pre-
processing, in each methylation profile there are still 392,761
molecular features, which is almost ten times larger than the
feature size of a gene expression profile. These methylation
features are separated into different fully connected blocks
according to their targeting chromosomes in order to reduce
the number of parameters in fully connected layers that encode
methylation data, prevent overfitting and save GPU memory
for training. Features in each chromosome are encoded into
corresponding vectors with 256 dimensions in the first hidden
layer to capture the intra-chromosome relationships, whereas
inter-chromosome relationships are obtained through the sec-
ond hidden layer. The two 1,024 dimensional vectors are
concatenated together in the second hidden layer and encoded
to a multi-omics vector. The final hidden layer of the encoder
fully connects to two output layers, which represent the mean
µ and the standard deviation σ in the Gaussian distribution
N (µ,σ) of the latent variable z given input sample x, which
is the variational distribution qφ(z|x). In order to make the
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Fig. 1. Diagram showing the architecture of OmiVAE. The network structure
is comprised of three main components: an encoder, a decoder, and a
classifier. Each rectangle denotes a fully connected (FC) block, the detailed
structure of which is shown in the gray box. FC blocks for gene expression
and DNA methylation data are marked in different colours. CpG sites in
methylation profiles are separated into different blocks according to their
targeting chromosomes. Model parallelism is applied by assigning the encoder
to GPU:0 and assigning decoder to GPU:1.
sampling step differentiable and suitable for backpropagation,
the reparameterization trick is applied as follows:
z = µ+ σ (3)
where  is a random variable sampled from the unit normal
distribution N (0, I). The dimension of the bottleneck layer
(i.e., µ, σ, and z) is normally set to 128. The outputs of the
bottleneck layer can also be used to visualise the clusters of
samples, and for this purpose the dimension of the bottleneck
layer can be set to 2 or 3 directly for 2D or 3D scatter plots.
The network structure of the decoder is similar to the mirror
image of the encoder network. Latent variable z is the input
of the decoder network followed by three hidden layers. The
output of the decoder is the reconstructed vector x′ which
consists of both the DNA methylation and gene expression
profile. As for the classifier, the output vector µ in the encoder
is connected to a three-layer classification network to predict
whether x is a tumour sample and the tumour type of this
sample. The output dimension of the classifier is set to 33 for
the tumour type classification and set to 34 for classification of
both the 33 tumour types and normal samples. This classifier
part adds further regularisation to the lower dimensional latent
representation with the classification task. In a basic VAE
model, the bottleneck layer tends to extract the most essential
features that can reconstruct input samples as closely as
possible. Nevertheless these extracted features may not be
related to specific task like tumour type classification. With
the regularisation of the classifier, the network is encouraged
to learn latent representations that can not only accurately
reconstruct the input sample but also identify cancer and
classify types.
Base on the aforementioned idea, the joint loss function of
the whole network can be defined as the combination of a VAE
loss and a classification loss. We denote the gene expression
profile of the input sample x as xe and the reconstructed
gene expression vector as x′e. For DNA methylation profile,
molecular features are grouped into 23 input vectors according
to their targeting chromosomes. These vectors are denoted as
xmj where j is the index of the corresponding chromosome.
The VAE loss can then be written as follows:
Lvae = 1
M
M∑
j=1
CE
(
xmj ,x
′
mj
)
+ CE (xe,x
′
e) + LKL (4)
where M is the number of chromosomes (23 in our case),
CE is the binary cross-entropy between input vectors and
reconstructed vectors, LKL is the KL divergence between the
learned distribution and a unit Gaussian distribution, which is:
LKL = DKL(N (µ,σ)‖N (0, I)). (5)
For the classifier, the ground truth label of a given sample x
is denoted as y, and the label predicted by the classifier is
denoted as y′. The classification loss can be defined as,
Lclass = CE(y, y′) (6)
where CE is the cross-entropy loss between the ground truth
and the predicted label. The total loss function of OmiVAE is
Ltotal = αLvae + βLclass (7)
and depends on α and β parameters which weight the two
main terms during training.
As for the model implementation, batch normalisation [20]
and certain activation functions are added in each fully con-
nected block. For most hidden layers, rectified linear units
(ReLU) [21] is selected as the activation function, whereas
sigmoid activation is applied to the output layer of the decoder
and softmax is attached to the final layer of the classifier.
The model was built in PyTorch (version 1.1) and trained on
two NVIDIA GeForce GTX 1080 Ti GPUs with 11 gigabytes
of memory each. In order to take full advantage of the
two GPUs and separate the enormous number of parameters
(∼ 7×108) into them, we applied a model parallelism strategy
that assigned the encoder to the first GPU and assigned
the decoder to the second GPU. The implementation of our
proposed model has been made publicly available on GitHub2.
IV. RESULTS
We demonstrated the performance of our model on the
aforementioned preprocessed multi-omics datasets which were
randomly divided into training, validation and testing sets, pro-
portionally allocating samples from each class. The network
architecture was implemented as same as the diagram shown
in Fig. 1. Adam optimiser [22] was utilised in this model
with the learning rate equaled to 10−3 and a batch size of 32.
The early stopping technique was applied to avoid overfitting
and we used stratified 10-fold cross-validation to robustly
evaluate the performance of OmiVAE and other methods to
avoid the bias from a single testing set. The training procedure
of OmiVAE was comprised of an unsupervised phase without
the classifier and a supervised phase with the classifier. In
the unsupervised phase, the weight β in (7) was set to 0
and no label information was used at this stage. OmiVAE
can be regarded as an unsupervised feature extraction and
dimensionality reduction model if only this phase is applied.
In the supervised phase, the weight β was set to 1 to extract
features that were related to the pan-cancer classification task
and classify samples in an end-to-end manner.
A. Unsupervised Phase
In our experiments, we first set the latent dimension directly
to 2 so as to visualise the latent space and evaluate the
2https://github.com/zhangxiaoyu11/OmiVAE
Fig. 2. 2D embedding of the multi-omics data learned by the unsupervised phase of OmiVAE (left) and PCA (right). Samples of various tumour types were
plotted with different colours shown in the legend. Normal samples were marked in black dots. The full names of the tumour type abbreviations can be found
on https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations.
Fig. 3. Multi-omics latent vectors of tumours and corresponding normal
samples from (a) kidney, (b) lung, (c) uterus and (d) breast learned by the
unsupervised phase of OmiVAE.
dimension reduction ability of OmiVAE. The two-dimensional
embedding of the 450,804 multi-omics features for all 9,081
samples learned by OmiVAE were plotted on a scatter graph
shown in the left-side of Fig. 2. As shown in the scatter
graph, a hierarchical cluster structure of input samples was
automatically formed through the latent space embedding of
OmiVAE. The higher-level clusters represent different organs
or systems. For a specific tissue-of-origin, samples of various
tumour subtypes and normal samples were grouped into cor-
responding lower-level clusters. These results indicate that the
low dimensional manifold learned by OmiVAE preserves both
the global and local clustering structures of the input samples.
In order to further evaluate the performance of the low di-
mensional embedding and delve into the two-level hierarchical
cluster structure of the latent space, we separately checked
samples from specific organs with different tumour subtypes
and normal samples. In the scatter graph shown in Fig. 3
(a), we selected all kidney samples in the TCGA datasets
from patients with three subtypes of kidney tumours, kidney
clear cell carcinoma (KIRC), kidney papillary cell carcinoma
(KIRP) and kidney chromophobe (KICH). Normal samples
from three different cohorts were mapped to the same cluster
through the 2-dimensional embedding of OmiVAE, and the
three subtypes of kidney tumours were also mapped to three
distinct clusters separately. We also investigated tumour types
and normal samples from lung, uterus, and breast, results of
TABLE I
CLASSIFICATION PERFORMANCE OF REPRESENTATIONS LEARNED BY
DIFFERENT DIMENSIONALITY REDUCTION METHODS
Accuracy Precision Recall F1 Score
PCA+SVM 30.13±1.62% 0.26±0.02 0.30±0.02 0.26±0.02
KPCA+SVM 30.16±1.65% 0.26±0.02 0.30±0.02 0.26±0.02
t-SNE+SVM 82.94±0.87% 0.80±0.01 0.83±0.01 0.80±0.01
UMAP+SVM 80.39±0.96% 0.73±0.01 0.80±0.01 0.76±0.01
OmiVAE+SVM
(1st phase, 2D) 84.40±0.75% 0.83±0.01 0.84±0.01 0.82±0.01
which were shown in Fig. 3 (b-d). In all of these scatter graphs,
normal samples can be easily separated from tumour ones
in the latent space. For lung and uterus, both of them have
two tumour subtypes which can be clearly distinguished from
each other in the low dimensional representation. The results
shown in Fig. 3 indicate that the representations of high-
dimensional multi-omics data learned by the unsupervised
phase of OmiVAE are discriminative for the downstream
classification tasks of tumour types and normal samples.
The performance of the unsupervised phase of OmiVAE
was compared with other feature extraction and dimensionality
reduction methods including the most widely-used algorithm
PCA, its non-linear variant KPCA, the popular manifold
learning method t-distributed stochastic neighbor embedding
(t-SNE) [23] and the latest dimension reduction technique
uniform manifold approximation and projection (UMAP) [24].
We first applied PCA to embed the same multi-omics dataset
to a 2D space. The low dimensional representations learned by
PCA were plotted on the scatter graph shown in the right-side
of Fig. 2. As can be seen in the two graphs, the 2D embedding
learned by PCA shows a much more mixed clustering structure
compared with that learned by the unsupervised phase of
OmiVAE. Samples of different tumour types are very difficult
to discriminate from each other. In order to evaluate the feature
extraction ability of OmiVAE and other existing methods in a
more quantified manner, we fed the 2D representations learned
by these methods to a support vector machine (SVM) with
a radial basis function (RBF) kernel and used the SVM to
classify tumour and normal samples (34 classes in total).
The classification performance of the five methods was
measured by four multi-class classification metrics: overall
accuracy, weighted precision, weight recall, and weighted F1
score. The performance results after 10-fold cross-validation
are shown in Table I. As we can see in the table, the 2D
representations learned by the unsupervised phase of OmiVAE
outperformed those learned by other dimensionality reduction
methods in all the four classification metrics. Note that the
metrics standard deviations of OmiVAE are also the least,
which indicates that the performance of OmiVAE is more
robust compared with other methods. The method with closest
performance to the unsupervised phase of OmiVAE is t-SNE.
In addition to the less discriminative extracted features, there
are also other drawbacks of t-SNE compared with OmiVAE.
TABLE II
CLASSIFICATION PERFORMANCE OF OMIVAE ON DIFFERENT TUMOUR
TYPES AND NORMAL SAMPLES (34 CLASSES)
Application Mode Accuracy F1 Score
Only Gene
Expression
OmiVAE+SVM
(unsupervised phase) 93.12±0.54% 0.926±0.006
OmiVAE
(end-to-end model) 96.37±0.46% 0.963±0.005
Only DNA
Methylation
OmiVAE+SVM
(unsupervised phase) 91.10±0.92% 0.899±0.010
OmiVAE
(end-to-end model) 96.37±0.70% 0.963±0.007
Multi-Omics
Data
OmiVAE+SVM
(unsupervised phase) 94.16±0.74% 0.937±0.008
OmiVAE
(end-to-end model) 97.49±0.45% 0.975±0.005
First, unlike OmiVAE, t-SNE is not a parametric method that
learns a mapping function which can be used for new data.
For data outside the training set, t-SNE needs to combine the
data together and rerun the whole process. Second, although t-
SNE is able to adequately keep the local clustering structures,
the global structure is not explicitly preserved. Finally, t-SNE
method can only embed data into two or three dimensional
space, while the dimension of the bottleneck layer of OmiVAE
can be set to any number.
B. Supervised Phase
In the supervised phase, the weight β in (7) was set
to 1 and labels were used to train the classifier. For the
classification task, the latent dimension was set to 128 to
preserve more information from the high-dimensional multi-
omics data during the whole training process including the
unsupervised phase, which can be considered as a pre-training
step in OmiVAE. Parameters of the encoder and the decoder
learned in the unsupervised phase were transferred to the
supervised phase and can still be fine-tuned to extract features
more related to the classification task during the second phase.
We first evaluated the classification performance of Omi-
VAE on the TCGA multi-omics datasets with both the tumour
samples and normal samples. There are 34 classes (33 tumour
types plus normal samples) in this multi-class classification
task. The results of OmiVAE on this task are shown in Table
II. Two application modes of OmiVAE were compared with
each other in the experiments. As can be seen in the table,
the classification performance of the end-to-end version of
OmiVAE is better than that of the model where features
learned by the unsupervised phase of OmiVAE were fed to
an SVM for classification. This could be due to that some
features extracted by the unsupervised phase of OmiVAE may
not be specifically related to the cancer classification task.
In order to test whether the information from different types
of omics data is complementary and can therefore improve
the performance of classification tasks, we applied the gene
expression dataset and DNA methylation dataset separately
Fig. 4. Visualisation of the classification space learned by the end-to-end
OmiVAE. t-SNE was applied to reduce the dimensionality from 128D to 2D
for scatter plotting.
to OmiVAE and evaluated the classification performance with
only one type of omics data. As shown in Table II, the results
obtained from gene expression data and DNA methylation
data are close to each other, while both of them are inferior
to the performance of multi-omics data, which occurred in
both application modes of OmiVAE (only the unsupervised
phase and the end-to-end mode). This indicates that the
complementary information from different omics datatypes is
combined together in the latent vector learned by OmiVAE to
extract more aspects of the input samples and can therefore
be helpful for biomedical tasks like cancer classification.
The average classification accuracy on different tumour
types and normal samples (34 classes) achieved by the end-to-
end OmiVAE is 97.49% after 10-fold cross-validation and the
standard deviation is 0.45%. As for the performance of other
methods, only Mostavi et al. [18] evaluated their model on
the 34-class task for both tumour and normal samples with an
accuracy of 95.0%. To further visualise the classification space
learned by OmiVAE, we used t-SNE to reduce the dimension
of latent vectors from 128 to 2 and plotted samples on a 2D
scatter graph shown in Fig. 4. Clusters of normal samples and
different types of tumour samples can be clearly recognised
in this scatter graph.
We also evaluated our method on the tumour type classi-
fication task specifically by removing all normal samples in
the TCGA multi-omics datasets. There are 33 classes corre-
sponding to 33 tumour types in this pan-cancer classification
TABLE III
CLASSIFICATION PERFORMANCE OF OMIVAE ONLY ON DIFFERENT
TUMOUR TYPES (33 CLASSES)
Application Mode Accuracy F1 Score
Only Gene
Expression
OmiVAE+SVM
(unsupervised phase) 93.66±0.57% 0.931±0.006
OmiVAE
(end-to-end model) 96.86±0.48% 0.968±0.005
Only DNA
Methylation
OmiVAE+SVM
(unsupervised phase) 92.04±0.38% 0.909±0.004
OmiVAE
(end-to-end model) 96.89±0.45% 0.968±0.005
Multi-Omics
Data
OmiVAE+SVM
(unsupervised phase) 94.51±0.48% 0.940±0.005
OmiVAE
(end-to-end model) 97.88±0.15% 0.979±0.002
task. The performance of OmiVAE on this task is shown in
Table III. The classification performance of both application
modes on the 33-class task is slightly better than those on the
34-class task. The average accuracy achieved by the end-to-
end OmiVAE is 97.88%, which outperformed other existing
methods [16]–[18] on the same classification task. In the
results, we can also observe that models trained on the multi-
omics data achieved better performance than those trained on
only one type of omics data, which we have mentioned earlier.
V. CONCLUSION
Different types of omics data reveal various aspects of the
same samples. Integrated analysis of multi-omics data allows
us to get a comprehensive picture of patients. However, the
number of available labeled samples and the dimensional-
ity of multi-omics data are normally mismatched, which is
called the “dimensionality curse”. To address this problem, we
proposed an end-to-end deep learning model called OmiVAE
for both low dimensional latent space extraction and multi-
class classification on multi-omics datasets. We integrated
genome-wide DNA methylation and gene expression profiles
together with more than 450,000 molecular features through
this model. A hierarchical cluster structure of samples can
be automatically formed without the need for labels during
the unsupervised phase of this model. In the supervised
phase, OmiVAE achieved an average classification accuracy
of 97.88% on different tumour types and 97.49% on tumour
types and normal samples after 10-fold cross-validation, which
is better than existing methods. Moreover, the OmiVAE model
learned from multi-omics data outperformed that using only
one type of omics data, which indicates that the comple-
mentary information from different omics datatypes provides
useful insights for biomedical tasks like cancer classification.
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